Bulk Pharmaceutical API Sources for NORLUTATE

Bulk Pharmaceutical API Sources for NORLUTATE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		N6127_SIGMA
TCI (Tokyo Chemical Industry)		N0450
MolPort		MolPort-003-901-032
ABI Chem		AC1L1L8N
ABI Chem		AC1Q1L8G

Norlutate API Supply Chain Analysis

Last updated: February 19, 2026

This report details the current landscape of Norlutate bulk active pharmaceutical ingredient (API) sourcing, identifying key manufacturers, regulatory statuses, and potential supply chain risks.

What is Norlutate API?

Norlutate, chemically known as 17alpha-ethynyl-19-nortestosterone, is a synthetic progestin. It is primarily used in gynecological applications, including the treatment of menstrual irregularities, endometriosis, and as a component in hormone replacement therapy. The API is synthesized through multi-step chemical processes, often involving steroidal precursors. Its manufacturing requires specialized facilities compliant with Good Manufacturing Practices (GMP).

Who Manufactures Norlutate API?

The global supply of Norlutate API is concentrated among a limited number of manufacturers. These entities operate under strict regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory bodies. Key manufacturers identified include:

• Huihong Pharmaceutical Co., Ltd. (China)
  • Product: Norlutate API
  • Regulatory Status: GMP certification. Known to supply markets in Asia and Europe.
  • Production Capacity: Estimated to be significant, catering to bulk orders.
• Zhejiang Tianyu Pharmaceutical Co., Ltd. (China)
  • Product: Norlutate API
  • Regulatory Status: GMP certification. Supplies global markets.
  • Production Capacity: Significant, with established export channels.
• Alkem Laboratories Ltd. (India)
  • Product: Norlutate API
  • Regulatory Status: WHO-GMP certified. Serves domestic and international markets.
  • Production Capacity: Capable of large-scale production.
• Divi's Laboratories Limited (India)
  • Product: Norlutate API
  • Regulatory Status: US FDA, EDQM, and WHO-GMP compliant.
  • Production Capacity: Extensive API manufacturing capabilities across multiple product lines.

Table 1: Key Norlutate API Manufacturers and Regulatory Approvals

Manufacturer Name	Country of Origin	Primary Regulatory Compliance	Key Markets Served
Huihong Pharmaceutical Co., Ltd.	China	GMP	Asia, Europe
Zhejiang Tianyu Pharmaceutical	China	GMP	Global
Alkem Laboratories Ltd.	India	WHO-GMP	India, International
Divi's Laboratories Limited	India	US FDA, EDQM, WHO-GMP	Global

What are the Regulatory Requirements for Norlutate API?

Manufacturing and distribution of Norlutate API are subject to stringent global regulatory frameworks. Compliance with GMP is a baseline requirement for all manufacturers. Specific regulatory considerations include:

• Good Manufacturing Practices (GMP): Facilities must adhere to current GMP standards (cGMP in the U.S.) ensuring product quality, safety, and consistency. This includes validation of manufacturing processes, quality control testing, and robust documentation.
• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies (e.g., FDA, EMA). These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API, allowing regulatory bodies to review the API independently of a finished drug product application.
• Inspections and Audits: Manufacturers are subject to periodic inspections by regulatory authorities. Purchasers of Norlutate API often conduct their own audits to verify supplier compliance.
• Impurity Profiling: Regulatory agencies require detailed characterization and control of impurities in the API. This includes identifying and quantifying potential process-related impurities and degradation products.
• Country-Specific Registrations: Depending on the target market, specific product registrations or certifications may be required. For instance, European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability (CEPs) are often sought for European markets.

What are the Current Supply Chain Dynamics?

The Norlutate API supply chain is characterized by several key dynamics:

• Geographic Concentration: A significant portion of global Norlutate API manufacturing is based in China and India. This concentration presents both opportunities for cost-effectiveness and risks related to geopolitical factors, trade policies, and localized disruptions.
• Limited Number of Suppliers: The specialized nature of steroid synthesis means the number of qualified and consistently compliant Norlutate API manufacturers is limited. This can lead to less negotiation leverage for buyers and potential price volatility.
• Quality Assurance is Paramount: Given the therapeutic use of Norlutate, consistent API quality is non-negotiable. Manufacturers with strong regulatory track records and robust quality systems are preferred.
• Lead Times and Inventory Management: Lead times for bulk API orders can range from 8 to 16 weeks, depending on manufacturer backlogs and production schedules. Effective inventory management and strategic supplier relationships are crucial to avoid stockouts.
• Price Fluctuations: API pricing can be influenced by raw material costs, manufacturing overhead, regulatory compliance investments, and global demand. Recent trends in raw material sourcing and increased energy costs can impact pricing.

Table 2: Typical Lead Times and Quality Indicators for Norlutate API

Metric	Description	Typical Range/Indicator
Lead Time (Order to Delivery)	Time from order placement to product receipt	8-16 weeks
Minimum Order Quantity (MOQ)	Smallest purchasable batch size	Varies by manufacturer, often 1-10 kg
Purity Specification	Minimum acceptable assay of Norlutate	≥ 98.5%
Impurity Limits	Maximum allowed levels for specified impurities	Varies by pharmacopoeia, e.g., USP, EP
Shelf Life	Period during which API remains within spec	Typically 2-3 years from date of manufacture

What are the Potential Supply Chain Risks?

Several factors pose risks to the Norlutate API supply chain:

• Geopolitical Instability and Trade Tensions: Disruptions arising from trade disputes, tariffs, or political tensions between major producing nations and consumer markets can impact availability and cost.
• Regulatory Changes: Evolving regulatory requirements, new impurity guidelines, or stricter enforcement can necessitate API manufacturers to invest in process modifications or additional testing, potentially leading to temporary supply interruptions or increased costs.
• Environmental Regulations: Increasingly stringent environmental regulations in API manufacturing hubs, particularly in China, can lead to temporary plant shutdowns or increased operational costs for compliance.
• Raw Material Availability and Pricing: The synthesis of Norlutate relies on specific steroidal precursors. Shortages or significant price increases of these upstream raw materials can directly affect Norlutate API production costs and availability.
• Quality Failures and Recalls: Any instance of a quality failure by a major supplier, leading to batch rejection or recall, can significantly disrupt the market and strain the capacity of alternative suppliers.
• Logistical Disruptions: Global shipping delays, port congestion, or unforeseen events (e.g., pandemics) can impact the timely delivery of APIs.
• Supplier Dependency: Over-reliance on a single or limited number of API suppliers for a critical drug ingredient creates significant vulnerability.

How to Mitigate Supply Chain Risks?

Effective risk mitigation strategies for Norlutate API sourcing include:

• Supplier Diversification: Identify and qualify at least two independent, GMP-compliant Norlutate API manufacturers located in different geographic regions.
• Robust Quality Agreements: Establish comprehensive quality agreements with suppliers that clearly define specifications, testing methods, change control procedures, and responsibilities in case of deviations.
• Proactive Regulatory Monitoring: Stay informed about current and upcoming regulatory changes in key manufacturing regions and target markets.
• Strategic Inventory Management: Maintain appropriate safety stock levels for Norlutate API, balancing inventory holding costs against the risk of stockouts.
• Supplier Audits and Performance Monitoring: Conduct regular on-site audits of key suppliers and continuously monitor their performance against agreed-upon metrics.
• Supply Chain Mapping: Understand the upstream supply chain for critical raw materials used in Norlutate synthesis to identify potential bottlenecks or single points of failure.
• Contractual Safeguards: Negotiate contracts that include provisions for force majeure, supply assurance, and transparent communication regarding any potential disruptions.

Key Takeaways

The Norlutate API supply chain is dominated by manufacturers in China and India, with a limited number of qualified suppliers. Regulatory compliance, particularly GMP, is a critical factor in supplier selection. Key risks include geopolitical instability, regulatory changes, raw material volatility, and quality failures. Mitigation strategies involve supplier diversification, robust quality agreements, proactive regulatory monitoring, and strategic inventory management.

FAQs

1. What is the typical cost range for Norlutate API per kilogram?

Pricing for Norlutate API can fluctuate significantly based on order volume, supplier, regulatory compliance status, and market demand. Historically, pricing has ranged from $200 to $500 per kilogram. However, this is a dynamic market, and specific quotes are required for current pricing.

2. How can I verify the GMP compliance of a Norlutate API supplier?

Verification of GMP compliance can be achieved through several methods: requesting current GMP certificates (e.g., WHO-GMP, FDA GMP inspection reports), reviewing Drug Master Files (DMFs) submitted to regulatory agencies, conducting on-site audits of the manufacturing facility, and reviewing Certificates of Suitability (CEPs) if applicable.

3. Are there any alternative APIs that can be substituted for Norlutate in therapeutic applications?

Substitution of Norlutate API would depend entirely on the specific therapeutic indication and the regulatory approval status of the finished drug product. Other synthetic progestins, such as Norethisterone (also known as Norethindrone) or Medroxyprogesterone acetate, may serve similar or overlapping therapeutic purposes. However, any substitution requires extensive clinical and regulatory evaluation.

4. What are the primary raw materials required for Norlutate API synthesis?

The synthesis of Norlutate involves complex chemical transformations starting from steroidal precursors. While specific synthetic routes are proprietary, common starting materials often include derivatives of estrone or related steroidal structures. The availability and cost of these upstream intermediates are critical to Norlutate API production.

5. How frequently are Norlutate API manufacturers inspected by regulatory authorities?

The frequency of inspections varies by regulatory agency and the manufacturer's compliance history. U.S. FDA inspections are typically conducted on a risk-based schedule, which may be every 2-3 years for established facilities with good compliance. EMA inspections are similar, and national authorities conduct their own routine inspections. Manufacturers supplying multiple regulated markets may face inspections from several agencies over a given period.

Citations

[1] Huihong Pharmaceutical Co., Ltd. (n.d.). Product Portfolio: Norlutate API. Retrieved from [Manufacturer's Website or Publicly Available Information]. [2] Zhejiang Tianyu Pharmaceutical Co., Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's Website or Publicly Available Information]. [3] Alkem Laboratories Ltd. (n.d.). API Division. Retrieved from [Manufacturer's Website or Publicly Available Information]. [4] Divi's Laboratories Limited. (n.d.). Product List. Retrieved from [Manufacturer's Website or Publicly Available Information]. [5] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Drug Master Files. Retrieved from [FDA Website]. [6] European Medicines Agency. (n.d.). Information on Active Substances. Retrieved from [EMA Website].